alpha-hydroxylinoleic acid
Small moleculeexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02201823)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- abtl0812
- abtl0812
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04431258 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2020 | Ability Pharmaceuticals SL |
| NCT03417921 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2019 | Ability Pharmaceuticals SL, The Cleveland Clinic |
| NCT03366480 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2016 | Ability Pharmaceuticals SL, Institut Català d'Oncologia, Universidad Autonoma de Barcelona, University of Seville, University of Valencia |
| NCT02201823 | Phase 1 | Feb 1, 2014 | Ability Pharmaceuticals SL, Institut Català d'Oncologia, University of Barcelona |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ability Pharmaceuticals SL | For profit | 4 | 4 | 2 | 2014 |
| Institut Català d'Oncologia | Academic/Hospital | 2 | 0 | 2 | 2014 |
| The Cleveland Clinic | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Universidad Autonoma de Barcelona | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Barcelona | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Seville | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Valencia | Academic/Hospital | 1 | 0 | 1 | 2016 |
7 organizations
Page 1 / 1